About Us

The global healthcare landscape is witnessing a growing demand for advanced breast cancer detection solutions. As digital mammography gains prominence, the need for superior imaging capabilities—especially for denser breast tissues—becomes evident. Alongside accuracy improvements, there’s a crucial requirement to streamline the screening process. AI-powered solutions are now essential for managing large datasets efficiently. Government initiatives promoting AI integration in healthcare further drive the adoption of these tools. Additionally, reducing radiologists’ workload makes AI invaluable for automating tasks and enhancing diagnostic procedures.

Advancing Breast Health, Empowering Lives

Sein Medical’s AI-driven precision and patient-centric approach redefine breast cancer detection, making early intervention a reality. Together, we save lives globally.

Sein Medical’s commitment to innovation and personalized treatment sets it apart in the evolving landscape of breast cancer detection. By integrating proprietary biomarker panels and AI algorithms, Sein Medical ensures unparalleled accuracy in analyzing mammogram images. Our user-friendly application seamlessly integrates into existing healthcare workflows, streamlining the screening process and optimizing resource utilization. With a vision for global expansion, our dynamic founders—Minoo Shahani, Dorsa Gharagozloo, and Fatemeh Ahmadpour—lead the charge in advancing Sein Medical’s presence in the Canadian healthcare industry. Together, we prioritize patient outcomes and save lives.

Company Overview

The rising adoption of digital mammography is propelled by its advanced imaging capabilities, particularly its ability to depict low-contrast objects and denser breast tissue more effectively. This shift is fueled by an increasing focus on early detection and screening for breast cancer. Countries across the globe are adopting these advanced systems to capitalize on their superior diagnostic accuracy, ultimately leading to improved patient outcomes. This trend underscores the critical role of advanced technologies in enhancing breast cancer diagnosis and reflects a global commitment to improving early detection and screening efforts.

Sein Medical is poised to meet the rising demand for advanced breast cancer detection and screening through its innovative solution. The Company’s software platform and patented technology will integrate AI
algorithms, deep learning methods, and biomarker panels to significantly enhance the accuracy and efficiency of mammogram screenings. By leveraging these advanced technologies, Sein Medical aims to
deliver a more reliable and precise screening process, thereby reducing the risks associated with false negatives and false positives.

The Company’s platform will be designed for seamless integration into existing healthcare systems, ensuring accessibility to private clinics, individuals, imaging labs, hospitals, and research facilities. The Company will also offer consultation and support services, ensuring a smooth implementation and operation of the technology. Moreover, the company’s solution will not only meet but will exceed the market demand for advanced breast cancer detection and screening. It will provide a cost-effective and easily accessible option for healthcare providers and patients alike, emphasizing the company’s commitment to improving breast cancer screening outcomes and ultimately saving lives.

Sein Medical is founded by three founders, Minoo Shahani as Chief Executive Officer, Dorsa Gharagozloo as Chief Clinical Officer and Fatemeh Ahmadpour as Chief Operating Officer, who will bring together a unique blend of expertise in the fields of biomedicine, biophysics, cancer biology, genetic engineering, and biotechnology. Their collective knowledge is aimed at advancing Sein Medical in the Canadian healthcare industry.